These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1972055)

  • 1. [Amisulpride, neuroleptic and antinegative action].
    Widlöcher D; Allilaire JF; Guérard des Lauriers A; Lecrubier Y
    Encephale; 1990; 16(2):159-63. PubMed ID: 1972055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
    Burns T; Bale R
    J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P; Canal M; Patat A; Bergougnan L; Zieleniuk I; Bianchetti G
    Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on amisulpride.
    Green B
    Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
    Peuskens J; Bech P; Möller HJ; Bale R; Fleurot O; Rein W
    Psychiatry Res; 1999 Nov; 88(2):107-17. PubMed ID: 10622347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
    Möller HJ; Boyer P; Fleurot O; Rein W
    Psychopharmacology (Berl); 1997 Aug; 132(4):396-401. PubMed ID: 9298518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The place of amisulpride in the atypical neuroleptic class].
    Perrault G; Schoemaker H; Scatton B
    Encephale; 1996 Jun; 22 Spec No 2():3-8. PubMed ID: 8767034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of dopamine research in schizophrenia.
    Pani L
    Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
    Cudennec A; Fage D; Bénavidès J; Scatton B
    Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.